Cargando…

A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy

BACKGROUND: Early death after a treatment can be seen as a therapeutic failure. Accurate prediction of patients at risk for early mortality is crucial to avoid unnecessary harm and reducing costs. The goal of our work is two-fold: first, to evaluate the performance of a previously published model fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jochems, Arthur, El-Naqa, Issam, Kessler, Marc, Mayo, Charles S., Jolly, Shruti, Matuszak, Martha, Faivre-Finn, Corinne, Price, Gareth, Holloway, Lois, Vinod, Shalini, Field, Matthew, Barakat, Mohamed Samir, Thwaites, David, de Ruysscher, Dirk, Dekker, Andre, Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108087/
https://www.ncbi.nlm.nih.gov/pubmed/29034756
http://dx.doi.org/10.1080/0284186X.2017.1385842
_version_ 1783350082563735552
author Jochems, Arthur
El-Naqa, Issam
Kessler, Marc
Mayo, Charles S.
Jolly, Shruti
Matuszak, Martha
Faivre-Finn, Corinne
Price, Gareth
Holloway, Lois
Vinod, Shalini
Field, Matthew
Barakat, Mohamed Samir
Thwaites, David
de Ruysscher, Dirk
Dekker, Andre
Lambin, Philippe
author_facet Jochems, Arthur
El-Naqa, Issam
Kessler, Marc
Mayo, Charles S.
Jolly, Shruti
Matuszak, Martha
Faivre-Finn, Corinne
Price, Gareth
Holloway, Lois
Vinod, Shalini
Field, Matthew
Barakat, Mohamed Samir
Thwaites, David
de Ruysscher, Dirk
Dekker, Andre
Lambin, Philippe
author_sort Jochems, Arthur
collection PubMed
description BACKGROUND: Early death after a treatment can be seen as a therapeutic failure. Accurate prediction of patients at risk for early mortality is crucial to avoid unnecessary harm and reducing costs. The goal of our work is two-fold: first, to evaluate the performance of a previously published model for early death in our cohorts. Second, to develop a prognostic model for early death prediction following radiotherapy. MATERIAL AND METHODS: Patients with NSCLC treated with chemoradiotherapy or radiotherapy alone were included in this study. Four different cohorts from different countries were available for this work (N = 1540). The previous model used age, gender, performance status, tumor stage, income depriv ation, no previous treatment given (yes/no) and body mass index to make predictions. A random forest model was developed by learning on the Maastro cohort (N = 698). The new model used performance status, age, gender, T and N stage, total tumor volume (cc), total tumor dose (Gy) and chemotherapy timing (none, sequential, concurrent) to make predictions. Death within 4 months of receiving the first radiotherapy fraction was used as the outcome. RESULTS: Early death rates ranged from 6 to 11% within the four cohorts. The previous model performed with AUC values ranging from 0.54 to 0.64 on the validation cohorts. Our newly developed model had improved AUC values ranging from 0.62 to 0.71 on the validation cohorts. CONCLUSIONS: Using advanced machine learning methods and informative variables, prognostic models for early mortality can be developed. Development of accurate prognostic tools for early mortality is important to inform patients about treatment options and optimize care.
format Online
Article
Text
id pubmed-6108087
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-61080872019-02-01 A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy Jochems, Arthur El-Naqa, Issam Kessler, Marc Mayo, Charles S. Jolly, Shruti Matuszak, Martha Faivre-Finn, Corinne Price, Gareth Holloway, Lois Vinod, Shalini Field, Matthew Barakat, Mohamed Samir Thwaites, David de Ruysscher, Dirk Dekker, Andre Lambin, Philippe Acta Oncol Article BACKGROUND: Early death after a treatment can be seen as a therapeutic failure. Accurate prediction of patients at risk for early mortality is crucial to avoid unnecessary harm and reducing costs. The goal of our work is two-fold: first, to evaluate the performance of a previously published model for early death in our cohorts. Second, to develop a prognostic model for early death prediction following radiotherapy. MATERIAL AND METHODS: Patients with NSCLC treated with chemoradiotherapy or radiotherapy alone were included in this study. Four different cohorts from different countries were available for this work (N = 1540). The previous model used age, gender, performance status, tumor stage, income depriv ation, no previous treatment given (yes/no) and body mass index to make predictions. A random forest model was developed by learning on the Maastro cohort (N = 698). The new model used performance status, age, gender, T and N stage, total tumor volume (cc), total tumor dose (Gy) and chemotherapy timing (none, sequential, concurrent) to make predictions. Death within 4 months of receiving the first radiotherapy fraction was used as the outcome. RESULTS: Early death rates ranged from 6 to 11% within the four cohorts. The previous model performed with AUC values ranging from 0.54 to 0.64 on the validation cohorts. Our newly developed model had improved AUC values ranging from 0.62 to 0.71 on the validation cohorts. CONCLUSIONS: Using advanced machine learning methods and informative variables, prognostic models for early mortality can be developed. Development of accurate prognostic tools for early mortality is important to inform patients about treatment options and optimize care. 2017-10-14 2018-02 /pmc/articles/PMC6108087/ /pubmed/29034756 http://dx.doi.org/10.1080/0284186X.2017.1385842 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Article
Jochems, Arthur
El-Naqa, Issam
Kessler, Marc
Mayo, Charles S.
Jolly, Shruti
Matuszak, Martha
Faivre-Finn, Corinne
Price, Gareth
Holloway, Lois
Vinod, Shalini
Field, Matthew
Barakat, Mohamed Samir
Thwaites, David
de Ruysscher, Dirk
Dekker, Andre
Lambin, Philippe
A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
title A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
title_full A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
title_fullStr A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
title_full_unstemmed A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
title_short A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
title_sort prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6108087/
https://www.ncbi.nlm.nih.gov/pubmed/29034756
http://dx.doi.org/10.1080/0284186X.2017.1385842
work_keys_str_mv AT jochemsarthur apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT elnaqaissam apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT kesslermarc apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT mayocharless apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT jollyshruti apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT matuszakmartha apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT faivrefinncorinne apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT pricegareth apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT hollowaylois apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT vinodshalini apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT fieldmatthew apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT barakatmohamedsamir apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT thwaitesdavid apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT deruysscherdirk apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT dekkerandre apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT lambinphilippe apredictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT jochemsarthur predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT elnaqaissam predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT kesslermarc predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT mayocharless predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT jollyshruti predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT matuszakmartha predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT faivrefinncorinne predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT pricegareth predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT hollowaylois predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT vinodshalini predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT fieldmatthew predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT barakatmohamedsamir predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT thwaitesdavid predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT deruysscherdirk predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT dekkerandre predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy
AT lambinphilippe predictionmodelforearlydeathinnonsmallcelllungcancerpatientsfollowingcurativeintentchemoradiotherapy